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Risk factors for neurocognitive 
impairment in patients with benign 
intracranial lesions
stefanie Bette1,4, Julia M. Ruhland2, Benedikt Wiestler1, Melanie Barz2, Bernhard Meyer2, 
Claus Zimmer1, Yu-Mi Ryang2, Florian Ringel2,3 & Jens Gempt2
this study was designed to assess risk factors for neurocognitive impairment in patients with benign 
intracranial lesions including tumors and vascular lesions. 74 patients (29 m, 51 f, mean age 54.4 years) 
with surgery for benign intracranial lesions were included in this prospective single-center study. 
Extensive neuropsychological testing was performed preoperatively, including tests for attention, 
memory and executive functions. Furthermore, headache and depression were assessed using the 
german version of the HDI (IBK) and the BDI-II. Multiple linear regression analyses of the percentile 
ranks (adjusted for age, sex and education) including the parameters age, Karnofsky Performance 
Status Scale (KPS), mood, pain and lesion size were performed to identify risk factors for cognitive 
impairment. Using the Mann-Whitney U test, the influence of hemisphere and type of lesion (tumor/
vascular) was assessed. Posthoc Bonferroni correction was performed. Poorer neurocognitive functions 
were observed only in the category attention in patients with higher age (divided attention, WMS) 
and reduced KPS (WMS). Lesion volume, mood, pain, hemisphere or the type of the lesion (tumor, 
vascular) were not identified as risk factors for poorer neurocognitive functions in patients with benign 
intracranial lesions. Age and KPS are the main risk factors for poorer neurocognitive functions in the 
category attention in patients with benign intracranial lesions. Knowledge of these risk factors might be 
important to find appropriate therapy regimes to improve cognitive functions and quality of life.
For patients with intracranial lesions, the most important recorded parameters are age, neurological status and 
functional independence, as measured by the Karnofsky Performance Status Scale (KPS)1. Recent studies ana-
lyzed the role of neurocognitive impairment for glioma patients and showed that cognitive function is a predic-
tor for survival2–5. The most common test to evaluate cognitive function is the mini-mental state examination 
(MMSE)6. Extensive neurocognitive testing is time-consuming and therefore not routinely used. Tumor loca-
tion and size, age, KPS and tumor grade as risk factors for neurocognitive impairment of glioma patients were 
identified3,7. Most studies about neurocognitive functions in brain tumor patients focus on fast growing tumors 
such as gliomas and/or metastases3,7–12. Benign lesions grow slowly, and therefore, less cognitive impairment was 
shown due to the plasticity of the brain13–15. Few studies have reported neurocognitive functions in meningioma 
patients or in patients with incidental meningiomas16,17; most of them, however, have focused on pre- and post-
operative comparisons14,18–23. Risk factors for neurocognitive impairment, such as tumor size and location, were 
identified20. A few studies also analyzed cognitive functions in patients with pituitary adenomas and unruptured 
intracranial aneurysms24–26. Patients with pituitary adenomas with suprasellar extension showed preoperative 
cognitive dysfunction that resolved two months after surgery25. For patients with unruptered aneurysms a slight 
cognitive dysfunction was observed after surgery26.
Very little is known about neurocognitive functions in patients with intracranial vascular lesions (except for 
intracranial aneurysms26,27) or rare intracranial tumors. Furthermore, many previous studies showed the sig-
nificant impact of pain on patients’ cognitive functions28. However, only a few studies assessed the relationship 
between trigeminal neuralgia and cognitive impairment29,30.
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There are—to our knowledge—no studies about neurocognitive functions of patients with benign intracranial 
lesions that include benign tumors and vascular lesions in one cohort.
The aim of this study was to assess preoperative neurocognitive functions in patients with benign intracranial 
lesions, to identify risk factors for cognitive impairment.
Methods
This prospective non-randomized single-center study was approved by the local ethics committee (Clinical Trial 
Registration Number: 3094/11) and conducted in accordance with the ethical standards of the 1964 Declaration 
of Helsinki and its later amendments31. Written informed consent was obtained from all study participants.
Patient population. From September 2012 to December 2014, patients with surgery for a benign intracra-
nial process were enrolled.
Inclusion criteria comprised informed consent, age ≥ 18 years, surgery for a benign intracranial process, pre-
operative magnetic resonance imaging (MRI) and sufficient knowledge of the German language. Exclusion crite-
ria were: age < 18 years, pregnancy, missing or retrieved informed consent, missing surgery or malign intracranial 
processes. As the extended test battery comprises many partially complex tests, only patients with a preoperative 
mini-mental status examination (MMSE) ≥ 18 were included in the study.
Study design. Preoperative tests were performed after informed consent and detailed information of the 
patient. Patients who met the inclusion criteria performed the basic test battery and the extended test battery as 
described below before surgery.
Age, preoperative KPS (ordinal scale 0–100 [%]) and tumor location (lobe, hemisphere) were recorded by 
qualified neurosurgeons for all patients.
Basic test battery. This test battery includes the well-known MMSE6, which measures the patients’ basic 
cognitive functions.
Extended test battery. Raw scores were adjusted for age, sex and education to a normative population 
(percentile ranks). Analyses were performed for the percentile ranks. For a few subtests, no percentile ranks were 
available: visual field subtests and Stroop’s failure. These data are not analyzed.
 (a) Attention
This study uses the test battery of attentional performance (TAP), a computer-based test battery described by 
Zimmermann et al.32. This battery was used to assess a broad range of cognitive deficits in the category attention 
and was selected by a neuropsychologist. No standardized test protocol is known for the measurement of impair-
ment of attention in brain tumor patients, the TAP test battery was used in a previous study about gliomas3.
Alertness. The subtest Alertness examines the reaction time. Visual stimuli are provided either with (TAP 
alertness W_sound) or without an acoustic notification (TAP alertness W_O_sound). Data are shown in milli-
seconds (ms) for delay of the patients’ reaction for tests with/without acoustic notification.
Divided attention. This subtest analyzes the simultaneous reaction to visual and acoustic stimuli (divided 
attention visual/auditory). Patients are challenged to react to both, visual stimuli (moving crosses, visual task) and 
acoustic stimuli (two consecutive sounds, auditory task). Data are shown as delay (ms) and mistakes/omissions.
Visual field. This subtest examines the patients’ visual field. The patients are requested to fix on one central 
point. Visual stimuli are provided; data are recorded for the right/left and central field of view and are shown as 
delay (ms) and omissions. As only raw data, and no percentile ranks were available for these subtests, no further 
analyses were performed.
Trail-Making-Test A (TMT-A). This is a well-known test for visual attention. Patients are asked to connect 
numbers (1–25) in the right order with a pencil. The test measures the time needed to correctly join all numbers33. 
Trail-Making-Tests assess the relations between speed and fluid intelligence, the TMT-A uses simple tasks34.
Wechsler Memory Scale (WMS). For this study, two subtests of the Wechsler Memory Scale revised was 
used35. The test consists of multiple subtests and analyzes verbal and non-verbal short-term memory. Patients are 
asked to perform tasks directly in the two subtests - the block-span and the digit-span subtest - as described pre-
viously3. Memory span (ms) and work memory (wm) are analyzed for verbal (v) and non-verbal (nv) short-term 
memory.
Both tests analyze patients’ immediate memory. As only subtests of short-term memory are used in this study, 
the results are presented in the attention category.
 (b) Memory
Verbal Learning and Memory Test (VLMT). VLMT - the German version of the well-known Rey 
Auditory-Verbal Learning Test - analyzes patients’ episodic memory function and consists of a learning and 
interference list with fifteen words each36. The learning list is read out five times (Dg1–5), followed by the inter-
ference list. Patients are asked to recite the words from the learning list directly (Dg6) and after 30 minutes (Dg7).
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Rey Osterrieth complex figure test (ROCF). Visual memory function is analyzed by this test37. A 
geometrical figure is shown to the patients, and then they are asked to draw the figure immediately (ROCF copy) 
and after 30 minutes (ROCF delay).
 (c) Executive functions
Trail-Making-Test B (TMT-B). In this subtest, patients are asked to connect letters and numbers with a 
pencil in the appropriate order (1-A-2-B-3-C)33. In contrast to the TMT-A, the TMT-B assesses patients’ ability to 
switch between tasks and therefore measures also fluid abilities34.
Regensburg Word Fluency Test (RWT). This test examines lexical and semantic fluency38. Patients are 
asked to say words with a specific letter (e.g., apple, auto, …) for one minute (lexical fluency). Semantic fluency 
is analyzed by naming words within a specific category (e.g., food). Furthermore, the ability to change between 
specific letters (turning lexical) and between specific categories (turning semantic) is tested.
Stroop Word Color Test. This test is also known as “color-word-interference-test” and examines selective 
attention and patients’ ability to inhibit cognitive interference. First, patients read the names of different colors 
(blue, green, yellow and red) written in black (word reading). Secondly, the patients are asked to name colored 
lines (line naming). Thirdly, there are differences between the written color and the color of the word (e.g., the 
word red is written in blue; interference).
Assessment of mood and pain. As mood and pain are known to influence neurocognition28,39, further 
measurements and tests were performed. To assess patients’ mood, the well-known Beck-Depression-Inventary II 
(BDI-II) was used in 61/80 patients40. The BDI-II score ranges from 0–63 (higher scores stand for higher extent of 
depression), the median of the normative population is 7.4 (population of n = 582 depressive patients and n = 260 
healthy controls, manual of Hautziger et al.41).
Headache was assessed using the IBK, the german version of the Headache Disability Inventory (HDI) in 
49/80 patients42. Headache is divided into four scales: no headache, slight headache, moderate headache, severe 
headache.
Volumetric measurement. Pre- and postoperative volumetric measurement of the intracranial lesion was 
performed by a neuroradiologist by semi-automatic manual segmentation (IPlannet Cranial 3.0, Fa. Brainlab, 
Munich, Germany). T1-weighted images after contrast agent were used for contrast-enhancing processes.
Statistical analysis. Statistical analysis was performed using IBM SPSS Statistics version 23.0 and 25.0 (SPSS 
Inc., IBM Corp., Armonk, NY, USA). Data are either shown as mean/standard deviation (normally-distributed 
data) or as median/interquartile range (IR; non-normally-distributed data). A multiple linear regression model 
was used to analyze the influence of different metric parameters (age, preoperative KPS, preoperative contrast 
enhancing tumor volume, mood, pain) on neurocognitive functions (attention, memory and executive func-
tions). The correlation matrix shows linear/non-linear relationships between dependent and independent varia-
bles. Only linear relationships were included for regression analyses. Correlations between independent variables 
were assessed by Spearman correlations. Independent variables did not show strong correlations (r < 0.8)43, there-
fore all three variables were assessed in the regression analysis (Table 1). Scatter plots for residuals of multiple 
linear regression analyses are recorded. Bonferroni correction was performed for the number of multiple linear 
regression analyses (n = 29) To assess the influence of nominal parameters (hemisphere, tumor vs. vascular) on 
neurocognitive functions, Mann-Whitney U tests with posthoc Bonferroni correction were performed. Analyses 
were performed for percentile ranks (values adjusted for age, education and sex). A P-value of <0.05 was defined 
as significant.
Ethical approval and informed consent. The study was conducted in accordance with the ethical stand-
ards of the 1964 Declaration of Helsinki and its later amendments and approved by the local ethics committee 
(Ethics committee technical university munich). Informed consent was signed by all study participants.
Age KPS Tumor volume Mood Pain
Age r = 1.0 P = 0.061, r = −0.219
P = 0.248, 
r = 0.144
P = 0.043, 
r = −0.271
P = 0.075, 
r = −0.271
KPS P = 0.061, r = −0.219 r = 1.0
P = 0.021, 
r = −0.284
P = 0.382, 
r = −0.119
P = 0.614, 
r = 0.078
Tumor volume P = 0.248, r = 0.144
P = 0.021, 
r = −0.284 r = 1.0
P = 0.560, 
r = 0.085
P = 0.910, 
r = −0.019
Mood P = 0.043, r = −0.271
P = 0.382, 
r = −0.119
P = 0.560, 
r = 0.085 r = 1.0
P = 0.040, 
r = 0.314
Pain P = 0.075, r = −0.271
P = 0.614, 
r = 0.078
P = 0.910, 
r = −0.019
P = 0.040, 
r = 0.314 r = 1.0
Table 1. Correlation matrix between independent variables.
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Results
Patient population. 81 patients met initially the inclusion criteria and were included in the study. One 
patient did receive neuroradiological intervention for an intracranial aneurysm and was excluded from the study. 
6 patients presented with trigeminal nerve neuralgia and were excluded due to a missing intracranial lesion. 
Therefore, the study population comprises 74 patients with the following benign lesions: meningioma (n = 31), 
pituitary adenoma (n = 14), vestibular schwannoma (n = 8), cavernoma (n = 6), intracranial aneurysm (n = 4), 
pineocytoma (n = 2), arterial–venous malformation (AVM; n = 2), hemangiopericytoma (n = 1), clivus chor-
doma (n = 1), colloidal cyst (n = 1), subependymoma (n = 1) and others (n = 3). For further analysis, lesions 
are assessed in two groups: tumor (including meningioma, pituitary adenoma, vestibular schwannoma, pine-
ocytoma, hemangiopericytoma, clivus chordoma, colloidal cyst and subependymoma) and vascular syndrome 
(including cavernoma, AVM and aneurysm). Median preoperative KPS was 100% (range 40–100). The median 
preoperative (contrast enhancing) volume of the intracranial lesions was 2.5 cm³ (IR 0.8–10.4 cm³) (Table 2).
Basic test battery. MMSE. Median preoperative MMSE was 29.0 (IR 27.8–30.0). Patients’ age showed a 
significant negative correlation to MMSE (r = −0.303, P = 0.009). Volume of the intracranial lesion did not cor-
relate to preoperative MMSE scores (r = 0.131, P = 0.296).
Furthermore, the type of intracranial lesion and location (lobe/hemisphere) were not significantly associated 
with MMSE.
Extended test battery. Attention. In the analysis of the percentile ranks, higher age predicted poorer 
functions only in 2/12 subtests (divided attention failure, WMS ms nv), higher KPS predicted better functions 
Age (mean [range]) Sex, male




- pituitary adenoma 14/74
- vestibular schwannoma 8/74
- cavernoma 6/74
- intracranial aneurysm 4/74
- pineocytoma 2/74
- arterio-venous malformation 2/74
- hemangiopericytoma 1/74
- clivus chordoma 1/74




- frontal lobe 28/74
- temporal lobe 9/74
- parietal lobe 3/74











Involvement of the insula 2/74
Intracerebral 51/74
Education
- elementary school 32/69
- intermediate education 20/69
- high school 17/69
Recurrent disease 14/74
Table 2. Patient population.
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in 1/12 subtests (WMS ms nv). Lesion volume, pain and mood did not show significant results in this analysis. 
(Figs 1 and 2, Table 3).
Memory. In the category memory none of the variables (age, KPS, tumor volume, mood, pain) predicted better 
or poorer neurocognitive functions (Table 3).
Executive functions. In the category executive functions, also none of the parameters predicted better or poorer 
neurocognitive functions (Table 3).
Tumor location/type of lesion. Prior to these analyses, important patient variables (age, mood, pain, tumor vol-
ume) are shown and compared in the different groups (divided in tumor location/hemisphere, and type of the 
lesion [tumor, vascular lesion]) (Table 4). Patients with tumors were significantly older than patients with vascular 
lesions (median 56.4 y. vs. 45.9 y, P = 0.031, U = 225, Z = −2.157). Patients with tumors in the left hemisphere 
showed significantly higher scores of the BDI-II (10.0 vs. 6.0, P = 0.049, U = 252, Z = −1.966). Tumor volume was 
significantly lower for tumors affecting the left hemisphere (1.6 cm³ vs. 6.2 cm³, P = 0.024, U = 348, Z = −2.264).
Tests for independent samples showed no significant differences of neurocognitive functions in all three cate-
gories in patients with tumors or vascular lesions, lesions in the left or right hemisphere.
Mood and pain. The median preoperative BDI-II of the patient cohort was 8.0 (IR: 1.3–15.0), therefore slightly 
higher than the normal population (median 7.4).
Higher scores of the BDI-II predicted poorer cognitive functions in none of the subtests (Table 3).
17/44 patients did not report preoperative headache, 15/44 patients presented with slight, 7/44 patients with 
moderate and 5/44 patients with severe headache.
Also pain did not predict poorer or better neurocognitive functions in all three categories (Table 3).
Figure 1. Risk factors for poorer cognitive functions in the attention category. Poorer cognitive functions are 
shown in Italics, and better neurocognitive functions is shown in Bold. DA: divided attention. WMS ms nv: 
Wechsler Memory Scale memory span non-verbal.
Figure 2. Scatter plots for risk factors age and KPS and neurocognitive functions in the subtests DA failure 
(divided attention failure) and WMS ms nv (Wechsler Memory Scale memory span non-verbal). KPS: 
Karnofsky Performance Status Scale.
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Discussion
This prospective single-center study analyzed neurocognitive functions in 74 patients with benign intracranial 
lesions including meningiomas, pituitary adenomas and vestibular schwannomas and vascular lesions (aneu-
rysm, cavernoma). Higher age predicted poorer functions only in subtests of the category attention (divided 
attention, WMS), not in the categories memory and executive functions. Lower KPS predicted poorer functions 
only in one subtest (WMS) in the category attention (WMS). Higher lesion volume, pain, mood, hemisphere or 
the type of the lesion (tumor, vascular) did not predict poorer or better neurocognitive functions in any of the 
three categories.
Analyses were performed for percentile ranks (values adjusted for age, sex and education). Most studies about 
neurocognitive functions in patients with benign intracranial lesions are either performed with analyses of val-
ues adjusted for age, sex and education22,46–48 or with analyses of matched-paired or healthy controls17,21,49. This 
prospective study only includes patients and no healthy controls, therefore analyses of values adjusted for age, sex 
and education (percentile ranks) were performed.
The main risk factors for poorer neurocognitive functions identified in this study cohort were higher age 
and reduced KPS. These results are similar to those of previous studies that included brain tumor patients3,8. 
Underlining the results of a previous study, age and KPS are more important risk factors than tumor location and 
size; these results are also confirmed in the patient cohort with benign intracranial lesions3.
For divided attention, significant poorer functions for patients with higher age. Poorer functions in immediate 
memory (analyzed by subtests of the Wechsler memory scale [WMS]) were observed for patients with higher age 
and lower KPS. These findings are in common with previous studies as age is a known predictor for cognitive 
dysfunction44,45.
Pain, especially chronic pain, is a known risk factor for neurocognitive impairment in all three categories28. 
Previous studies reported impaired working memory and poorer scores in the Wechsler Memory Scale for 
patients with chronic and induced pain50–52. The exact pathomechanisms are still unknown; studies showed that 
patients with chronic pain show poorer memory function than patients with induced pain, suggesting also other 














Attention TAP Alertness W_O_sound 0.037 1.815 0.154 1.0 24.370 2.362 n.s. n.s. n.s. — —
Alertness W_sound 0.015 1.322 0.276 1.0 24.370 2.298 n.s. n.s. n.s. — —
Alertness phasic 0.064 3.150 0.050 20.208 2.205 — n.s. n.s. — —
Divided attention visual 0.032 2.028 0.140 1.0 20.205 2.088 — n.s. n.s. — —
Divided attention auditive 0.006 1.056 0.394 1.0 21.844 2.147 — n.s. n.s. n.s. n.s.
Divided attention failure* 0.209 6.468 0.001 0.029 24.241 1.650 <0.001 n.s. n.s. — —
Divided attention selected 0.107 2.110 0.102 1.0 10.039 1.991 n.s. — n.s. n.s. n.s.
TMT-A TMT-A 0.069 3.351 0.042 22.884 1.810 — n.s. n.s. — —
WMS WMS ms v 0.032 3.435 0.068 19.237 2.012 — n.s. — — —
WMS wm v 0.022 1.722 0.187 1.0 7.874 1.923 n.s. — n.s. — —
WMS ms nv* 0.226 7.320 <0.001 0.029 24.674 2.365 0.001 0.023 n.s. — —
WMS wm nv 0.163 2.897 0.036 1.0 22.238 2.233 n.s. n.s. n.s. — n.s.
Memory VLMT VLMT Dg1 0.087 1.906 0.132 1.0 9.970 2.292 n.s. — n.s. n.s. n.s.
VLMT Dg5 0.187 3.238 0.023 0.667 22.238 2.154 n.s. n.s. n.s. — n.s.
VLMT Dg1-5 0.218 3.722 0.013 0.377 22.238 2.015 n.s. n.s. n.s. — n.s.
VLMT Dg6 0.053 1.546 0.210 1.0 22.238 2.033 n.s. n.s. n.s. — n.s.
VLMT Dg7 0.108 2.185 0.091 1.0 22.238 2.084 n.s. n.s. n.s. — n.s.
VLMT Dg5-6 −0.005 0.942 0.431 1.0 3.619 2.413 — — n.s. n.s. n.s.
VLMT Dg5-7 −0.015 0.806 0.499 1.0 8.809 2.120 n.s. — n.s. — n.s.
ROCF ROCF copy 0.123 3.955 0.027 0.783 8.376 1.949 n.s. — — — n.s.
ROCF delay 0.075 2.710 0.079 1.0 8.376 2.461 n.s. — — — n.s.
Executive 
functions Stroop’s Stroop’s word reading −0.009 0.859 0.469 1.0 9.202 1.934 n.s. — n.s. n.s. —
Stroop’s naming 0.030 1.283 0.297 1.0 26.025 1.821 — n.s. n.s. n.s. n.s.
Stroop’s interference 0.106 2.825 0.050 1.0 26.025 1.682 — n.s. n.s. n.s. —
RWT RWT lexical −0.008 0.921 0.463 1.0 22.280 1.947 — n.s. n.s. n.s. n.s.
RWT semantic 0.248 3.502 0.012 0.348 24.942 2.151 n.s. n.s. n.s. n.s. n.s.
RWT turning lexical 0.139 2.577 0.054 1.0 22.238 1.317 n.s. n.s. n.s. — n.s.
RWT turning semantic 0.230 4.884 0.006 0.174 19.155 1.843 — n.s. n.s. — n.s.
TMT-B TMT-B 0.096 1.761 0.150 1.0 28.975 1.524 n.s. n.s. n.s. n.s. n.s.
Table 3. Attention. Multiple linear regression analysis for the attention category. Only significant p-values 
(<0.05) are shown. Better neurocognitive functions are listed in Bold, poorer neurocognitive functions in Italic.
7Scientific RepoRts |          (2019) 9:8400  | https://doi.org/10.1038/s41598-019-44466-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
as a significant predictor for poorer neurocognitive functions. This might be explained by the fact that patients 
with tumors or vascular lesions do not present with pain, but with other symptoms like seizures or neurological 
deficits.
Mood was not shown as significant predictor for cognitive dysfunction in this patient cohort. These results 
are contrary to previous findings that showed depression as an important predictor for neurocognitive impair-
ment53–56. In the patient cohort of this study the values of the BDI-II were comparable to the values of the normal 
population. Most studies showed cognitive impairment mostly for patients with major depression, this might 
explain the conflicting results.
Episodic memory function (analyzed by the Verbal Learning and Memory Test [VLMT]) was poorer in 
patients with higher age and lower KPS. These results are in common with a previous study that showed poorer 
episodic memory function in a cognitively normal elderly cohort suggesting dysfunction in the posterior cingu-
late region as an important factor57.
Lesion volume was not shown as a significant predictor for poorer cognitive. Previous studies reported that 
verbal fluency was impaired in patients with larger tumor volume3,20. These discrepancies might be explained by 
the patient cohort of this study. We included only patients with benign, predominantly small lesions. Another 
explanation for these findings might be neuroplasticity.
Neuroplasticity is a known phenomenon for patients with infiltrating brain tumors, especially slowly growing 
tumors like diffuse gliomas58. In this cohort we assessed benign and therefore slowly growing lesions, therefore 
neuroplasticity might influence the results of this study. This might also explain the results that mainly age and 
KPS affect patients’ cognitive functions.
No significant differences between vascular and tumoral lesions were observed in this patient cohort. These 
findings might be explained by the fact that only benign tumors were included in this study.
Previous studies reported cognitive functions for patients with predominantly only one tumor/lesion entity, 
e.g. meningioma, pituitary adenoma, trigeminal neuralgia or aneurysm16,19,24–27,30. In this study, patients with 
different intracranial lesion were assessed in one cohort. This introduces a large heterogeneity of the cohort, and 
it is not possible to draw conclusions for one tumor entity. However, cognitive functions for single entities were 
analyzed in previous studies. This study points out that in a cohort of patients with tumoral and vascular lesions 
the type of the lesion is no predictor for neurocognitive dysfunction. The main predictors for cognitive dysfunc-
tion are the known variables – age and KPS.
This study has limitations. The main limitation is the high variety of diseases and therefore a low number, 
respectively. However, rare tumors such as chordoma and subependymoma as well as rare vascular lesions like 
cavernomas were assessed. No conclusions can be drawn for single lesion entities according to the results of this 
study.
No comparisons between the study population and a normative cohort were performed; this, however, has 
been shown in previous studies for patients with benign intracranial tumors17,21,22,47,48,59. The results of this study 
are mainly compared to studies on meningioma patients, also the cited studies with comparisons to the normative 
cohort were mainly performed on meningioma patients. However, the patient cohort of this study only includes 
31/80 meningioma patients which might involve a bias. As described above, only a few studies previously assessed 
cognitive functions in patients with other benign intracranial tumors and vascular lesions, therefore comparabil-
ity is low and further studies are necessary to draw conclusions and to assess cognitive functions in comparison 
to a normative cohort in patients with rare intracranial lesions.
Another limitation might be the manual segmentation of the lesions. Especially for small lesions and for 
lesions at the skull base this might introduce a bias due to over- or underestimation of lesion volume60.
Conclusions
Main risk factors for poorer neurocognitive functions in the category attention, not in the categories memory and 
executive functions, are higher age and reduced KPS in patients with benign intracranial lesions. Higher lesion 
volume, lesion location, type of the lesion (tumor, vascular), mood and pain did not predict poorer or better 
neurocognitive functions. As neurocognitive impairment influences patients’ quality of life, knowledge of these 




Age P-value Mood P-value Pain P-value Volume P-value








Right hemisphere not affected 58.6 y. 5.0 0.0 1.7 cm³

















Vascular lesion 45.9 y. 2.0 0.0 1.0 cm³
Table 4. Comparison of variables age, mood, pain and tumor volume in the different groups. Median scores are 
shown. For mood, the scores of the BDI-II are reported (points), for pain, the scores of the IBK (points). Data of 
volume are shown as the volume of the contrast enhancing preoperative tumor (cm³); y = years.
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